N Engl J Med. 2025 Jan 16;392(3):249-257. IF: 96.2Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.www.nejm.org/doi/10.1056/NEJMoa2406070 N Engl J Med. 2025 Jan 16;392(3):310-311. IF: 96.2Inavolisib Therapy in Advanced Breast Cancer.www.nejm.org/doi/10.1056/NEJMc2415114 Nat Med. 2025 Jan 15. IF: 58.7Menstrual cycle linked to breast cancer chemotherapy response.www.nature.com/articles/d41591-025-00004-0 Ann Oncol. 2025 Jan 15. IF: 56.7ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update.www.annalsofoncology.org/article/S0923-7534(24)04980-9/fulltext Nature. 2025 Jan 15. IF: 50.5Targeting FOXM1 condensates reduces breast tumour growth and metastasis.www.nature.com/articles/s41586-024-08421-w Nat Methods. 2025 Jan 15. IF: 36.1Probing the physical hallmarks of cancer.www.nature.com/articles/s41592-024-02564-4 Nat Genet. 2025 Jan 15;57:2. IF: 31.7Mutations in healthy breast tissue.www.nature.com/articles/s41588-024-02060-7 Adv Mater. 2025 Jan 15. IF: 27.4Leveraging Optical Anisotropy of the Morpho Butterfly Wing for Quantitative, Stain-Free, and Contact-Free Assessment of Biological Tissue Microstructures.www.onlinelibrary.wiley.com/doi/10.1002/adma.202407728 JAMA Surg. 2025 Jan 15. IF: 15.7Multicomponent Deimplementation Strategy to Reduce Low-Value Preoperative Testing.www.jamanetwork.com/journals/jamasurgery/fullarticle/2829134 JAMA Surg. 2025 Jan 15. IF: 15.7Effective Deimplementation of Low-Value Preoperative Testing: Choosing Wisely, From Policy to Practice.www.jamanetwork.com/journals/jamasurgery/fullarticle/2829138 Nat Commun. 2025 Jan 15;16:687. IF: 14.7Injectable supramolecular hydrogel co-loading abemaciclib/NLG919 for neoadjuvant immunotherapy of triple-negative breast cancer.www.nature.com/articles/s41467-025-55904-z Nat Commun. 2025 Jan 15;16:706. IF: 14.7Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models.www.nature.com/articles/s41467-024-55770-1 Nat Commun. 2025 Jan 15;16:703. IF: 14.7Illuminating the impact of N-terminal acetylation: from protein to physiology.www.nature.com/articles/s41467-025-55960-5 Nat Commun. 2025 Jan 15;16:677. IF: 14.7Robust genome editing activity and the applications of enhanced miniature CRISPR-Cas12f1.www.nature.com/articles/s41467-025-56048-w Nat Commun. 2025 Jan 15;16:680. IF: 14.7Causality-driven candidate identification for reliable DNA methylation biomarker discovery.www.nature.com/articles/s41467-025-56054-y Adv Sci (Weinh). 2025 Jan 15. IF: 14.3Pristimerin Promotes Ubiquitination of HSPA8 and Activates the VAV1/ERK Pathway to Suppress TNBC Proliferation.www.onlinelibrary.wiley.com/doi/10.1002/advs.202413174 Small. 2025 Jan 15. IF: 13.0Combining Top-Down and Bottom-Up: An Open Microfluidic Microtumor Model for Investigating Tumor Cell-ECM Interaction and Anti-Metastasis.www.onlinelibrary.wiley.com/doi/10.1002/smll.202402499 Nat Chem Biol. 2025 Jan 14. IF: 12.9Synergistic protection of nascent DNA at stalled forks by MSANTD4 and BRCA1/2-RAD51.www.nature.com/articles/s41589-024-01833-9 Sci Adv. 2025 Jan 15;11(3):eadr7934. IF: 11.7CD4(+)FOXP3Exon2(+) regulatory T cell frequency predicts breast cancer prognosis and survival.www.science.org/doi/10.1126/sciadv.adr7934 Sci Adv. 2025 Jan 15;11(3):eadp9009. IF: 11.7Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells.www.science.org/doi/10.1126/sciadv.adp9009 JAMA Netw Open. 2025 Jan 14;8(1):e2454000. IF: 10.5Preferred and Actual Location of Death in Adolescents and Young Adults With Cancer.www.jamanetwork.com/journals/jamanetworkopen/fullarticle/2829188 JAMA Netw Open. 2025 Jan 14;8(1):e2453972. IF: 10.5Location of Death Preferences in Adolescents and Young Adults With Cancer.www.jamanetwork.com/journals/jamanetworkopen/fullarticle/2829189 Genome Med. 2025 Jan 14;17(1):3. IF: 10.4TP53 germline testing and hereditary cancer: how somatic events and clinical criteria affect variant detection rate.www.biomedcentral.com/articles/10.1186/s13073-025-01429-5 Exp Hematol Oncol. 2025 Jan 15;14(1):6. IF: 9.4Construction and characterization of chimeric FcγR T cells for universal T cell therapy.www.biomedcentral.com/articles/10.1186/s40164-025-00595-x
